<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2023/05/nasdaq-statistics-scaled.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2023/05/nasdaq-statistics-scaled.jpg"/></p>
<p>納斯達克最近宣佈將 Procaps Group 除名，原因是其未能按時完成財務報告標準，這一重大決定突顯了企業在遵守監管規定方面面臨的困難。</p>
<p>納斯達克的官方公告確認，該除名將於 2 月 4 日生效。</p>
<p>這一舉措標誌着這家制藥公司面臨的重大轉折點，現在必須應對場外交易（OTC）專家市場的問題。</p>
<h2>Procaps 除名的影響</h2>
<p>根據納斯達克的説法，Procaps Group 未能按時提交重要財務報告，導致該公司退出市場。</p>
<p>根據當地媒體《共和國報》的報道，除名是由於 Procaps 未能滿足財務報告提交的截止日期。</p>
<p>在過渡到 OTC 專家市場期間，Procaps 承諾保持其運營的完整性，並遵守向證券交易委員會（SEC）的頻繁通知，同時預計其當前商業活動不會發生變化。</p>
<p>除名可能對該組織產生重大影響，特別是在投資者關係和現金流方面。</p>
<p>自成為上市公司以來，Procaps 的股價已下降約 89%，與其初始定價相比大幅下滑。</p>
<p>根據彭博社的分析，最近一次交易中股價跌至 1.12 美元，而去年為 4.41 美元。</p>
<h2>董事會和管理層變動</h2>
<p>為應對這些挑戰，Procaps 決定立即對董事會進行調整，以恢復公司的市場地位。梅麗莎·安傑利尼女士和卡米洛·卡馬喬先生被任命為新任臨時聯合首席執行官，這是董事會在除名後戰略性決定的一部分。</p>
<p>前首席執行官何塞·安東尼奧·維埃拉在過渡階段辭職。</p>
<p>領導層變動的公告是對 Procaps 公司治理和運營效率進行更大範圍、急需審查的一部分。</p>
<p>根據納斯達克的説法，除名可能加劇投資者對該公司公司治理和運營缺陷的擔憂，這些問題必須迅速解決，以便公司重新獲得投資者信心。</p>
<h2>在萎縮市場中的前景</h2>
<p>儘管 Procaps 努力向投資者保證日常運營將照常進行，但過渡到 OTC 專家市場可能導致投資者的懷疑，從而導致股市流動性下降。</p>
<p>這一舉措可能會加劇 Procaps 在獲取資金和與重要市場參與者建立聯繫方面已經面臨的困難。</p>
<p>事情很快會恢復正常，因為該公司的下一步預計將專注於恢復運營、重建投資者信心，並通過遵守市場規定來減少錯誤財務報告的數量。</p>
<p>最終，持續發展的長期道路和與股東的開放溝通將使 Procaps 更有效地應對這些困難時期。</p>
<p>總之，Procaps Group 從納斯達克除名為其他處於類似情況的公司敲響了警鐘。</p>
<p>隨着公司進入 OTC 專家市場的新階段，強有力的領導和適當的治理將對其恢復和重建投資者信任至關重要。</p>
<p>困難是巨大的，但通過正確的方法和透明度的承諾，Procaps 可能能夠重新進入製藥行業。</p>
<p>這篇文章的標題是《納斯達克因財務短缺將哥倫比亞的 Procaps Group 除名》，首次出現在 Invezz 上。</p>

PRCWF

PROCW

PROC

PROCF

<p>納斯達克已宣佈由於未能滿足財務報告標準，將於 2 月 4 日將哥倫比亞的 Procaps Group 退市。此決定突顯了企業在合規方面面臨的挑戰。自上市以來，Procaps 的股價已暴跌 89%，將轉向 OTC 專家市場，同時保持運營的完整性。該公司已任命新的臨時聯合首席執行官，並正在進行治理審查。退市引發了對投資者信心的擔憂，並可能影響融資和市場關係</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2023/05/nasdaq-statistics-scaled.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2023/05/nasdaq-statistics-scaled.jpg"/></p>
<p>Nasdaq recently announced the removal of the Procaps Group due to its failure to complete financial reporting standards on time, a significant decision that illustrates the difficulty that businesses confront in maintaining compliance with regulatory specifications.</p>
<div class="lb-trans"><p>納斯達克最近宣佈將 Procaps Group 除名，原因是其未能按時完成財務報告標準，這一重大決定突顯了企業在遵守監管規定方面面臨的困難。</p>
</div><p>Nasdaq’s official announcement confirms that the expulsion will take effect on February 4.</p>
<div class="lb-trans"><p>納斯達克的官方公告確認，該除名將於 2 月 4 日生效。</p>
</div><p>This move marks a watershed moment for the pharmaceutical company, which now must deal with the problems of the Over-The-Counter (OTC) Expert Market.</p>
<div class="lb-trans"><p>這一舉措標誌着這家制藥公司面臨的重大轉折點，現在必須應對場外交易（OTC）專家市場的問題。</p>
</div><h2>Effects of Procaps delisting</h2>
<div class="lb-trans"><h2>Procaps 除名的影響</h2>
</div><p>According to Nasdaq, the Procaps Group failed to meet the deadlines for significant financial reports, prompting the company’s withdrawal from the market.</p>
<div class="lb-trans"><p>根據納斯達克的説法，Procaps Group 未能按時提交重要財務報告，導致該公司退出市場。</p>
</div><p>According to local media La Republica, the delisting occurred due to Procaps’ inability to meet financial report filing deadlines.</p>
<div class="lb-trans"><p>根據當地媒體《共和國報》的報道，除名是由於 Procaps 未能滿足財務報告提交的截止日期。</p>
</div><p>During the transition to the OTC Expert Market, Procaps is committed to maintaining its operational integrity and complying with frequent notifications to the Securities and Exchange Commission (SEC), while no changes are expected in its current commercial activities.</p>
<div class="lb-trans"><p>在過渡到 OTC 專家市場期間，Procaps 承諾保持其運營的完整性，並遵守向證券交易委員會（SEC）的頻繁通知，同時預計其當前商業活動不會發生變化。</p>
</div><p>Delisting could have a significant impact on the organization, particularly in terms of investor relationships and cash flow.</p>
<div class="lb-trans"><p>除名可能對該組織產生重大影響，特別是在投資者關係和現金流方面。</p>
</div><p>Since becoming a public business, Procaps’ stock price has fallen by around 89%, a considerable reduction from its initial pricing.</p>
<div class="lb-trans"><p>自成為上市公司以來，Procaps 的股價已下降約 89%，與其初始定價相比大幅下滑。</p>
</div><p>According to Bloomberg’s analysis, the stock price fell to $1.12 in the most recent trading session, compared to $4.41 the prior year.</p>
<div class="lb-trans"><p>根據彭博社的分析，最近一次交易中股價跌至 1.12 美元，而去年為 4.41 美元。</p>
</div><h2>Board and management shakeup</h2>
<div class="lb-trans"><h2>董事會和管理層變動</h2>
</div><p>To address these challenges, Procaps has chosen to make immediate changes to its board of directors to restore the company’s market status. Ms. Melissa Angelini and Mr.</p>
<div class="lb-trans"><p>為應對這些挑戰，Procaps 決定立即對董事會進行調整，以恢復公司的市場地位。梅麗莎·安傑利尼女士和卡米洛·卡馬喬先生被任命為新任臨時聯合首席執行官，這是董事會在除名後戰略性決定的一部分。</p>
</div><p>Camilo Camacho has been named as the new interim co-CEO by the board as part of a strategic decision to modify the company’s course following its delisting.</p>
<div class="lb-trans"><p>前首席執行官何塞·安東尼奧·維埃拉在過渡階段辭職。</p>
</div><p>José Antonio Vieria, the former CEO, resigned during the transition phase.</p>
<div class="lb-trans"><p>領導層變動的公告是對 Procaps 公司治理和運營效率進行更大範圍、急需審查的一部分。</p>
</div><p>The announcement of the leadership transition is part of a larger, much-needed review of Procaps’ corporate governance and operational efficiency.</p>
<div class="lb-trans"><p>根據納斯達克的説法，除名可能加劇投資者對該公司公司治理和運營缺陷的擔憂，這些問題必須迅速解決，以便公司重新獲得投資者信心。</p>
</div><p>According to Nasdaq, the delisting may exacerbate investors’ concerns about the business’s corporate governance and operational shortcomings, which must be addressed quickly for the company to regain investor confidence.</p>
<div class="lb-trans"><h2>在萎縮市場中的前景</h2>
</div><h2>Prospects in a shrinking market</h2>
<div class="lb-trans"><p>儘管 Procaps 努力向投資者保證日常運營將照常進行，但過渡到 OTC 專家市場可能導致投資者的懷疑，從而導致股市流動性下降。</p>
</div><p>Despite Procaps’ efforts to assure investors that everyday operations will continue as usual, the transition to the OTC Expert Market may lead to investor scepticism and, as a result, a drop in stock market liquidity.</p>
<div class="lb-trans"><p>這一舉措可能會加劇 Procaps 在獲取資金和與重要市場參與者建立聯繫方面已經面臨的困難。</p>
</div><p>This action could exacerbate Procaps’ already tough situation in acquiring funding and developing ties with important market participants.</p>
<div class="lb-trans"><p>事情很快會恢復正常，因為該公司的下一步預計將專注於恢復運營、重建投資者信心，並通過遵守市場規定來減少錯誤財務報告的數量。</p>
</div><p>Things will return to normal soon since the company’s next step is expected to focus on resuming operations, restoring investor faith, and reducing the amount of incorrect financial reports by adhering to market regulations.</p>
<div class="lb-trans"><p>最終，持續發展的長期道路和與股東的開放溝通將使 Procaps 更有效地應對這些困難時期。</p>
</div><p>Eventually, the long-term path of sustained development and open communication with shareholders will enable Procaps to navigate these difficult times more effectively.</p>
<div class="lb-trans"><p>總之，Procaps Group 從納斯達克除名為其他處於類似情況的公司敲響了警鐘。</p>
</div><p>In conclusion, Procaps Group’s delisting from Nasdaq serves as a warning to other companies in similar situations.</p>
<div class="lb-trans"><p>隨着公司進入 OTC 專家市場的新階段，強有力的領導和適當的治理將對其恢復和重建投資者信任至關重要。</p>
</div><p>As the company enters this new phase in the OTC Expert Market, strong leadership and adequate governance will be critical in guiding it to recovery and regaining investors’ trust.</p>
<div class="lb-trans"><p>困難是巨大的，但通過正確的方法和透明度的承諾，Procaps 可能能夠重新進入製藥行業。</p>
</div><p>The difficulties are substantial, but with the right approaches and promises of transparency, Procaps may be able to re-enter the pharmaceutical sector.</p>
<div class="lb-trans"><p>這篇文章的標題是《納斯達克因財務短缺將哥倫比亞的 Procaps Group 除名》，首次出現在 Invezz 上。</p>
</div><p>The post Nasdaq delists Colombia’s Procaps Group due to financial shortfalls appeared first on Invezz</p>

納斯達克因財務短缺將哥倫比亞的 Procaps Group 摘牌